Literature DB >> 7743011

Paroxysmal atrial fibrillation: a need for classification.

S Lévy1, P Novella, P Ricard, F Paganelli.   

Abstract

UNLABELLED: Classification of Atrial Fibrillation.
INTRODUCTION: Clinical aspects of paroxysmal atrial fibrillation are heterogeneous. The attacks of atrial fibrillation may differ in their duration frequency and presence and severity of symptoms. Therefore, a proposal for a clinical classification of paroxysmal atrial fibrillation may be helpful. We tested a new classification system in a cohort of 51 consecutive hospitalized patients with paroxysmal atrial fibrillation. METHODS AND
RESULTS: Paroxysmal atrial fibrillation was subdivided into three classes. Class I included a first attack of symptomatic atrial fibrillation either with spontaneous termination (IA) or requiring cardioversion because of poor tolerance (IB). Class II included recurrent attacks in untreated patients within three subgroups: IIA with no symptoms, IIB with < 1 symptomatic attack per 3-month period, and IIC > with 1 symptomatic attack per 3-month period. Class III included recurrent atrial fibrillation unresponsive to one or more antiarrhythmic agents for prevention of recurrences. Class III also consisted of three subgroups: IIIA with no or mild symptoms, IIIB with < 1 symptomatic attack per 3-month period, and IIIC with > 1 symptomatic attack per 3-month period. The criteria for paroxysmal atrial fibrillation (episode > 2 minutes and < 7 days in duration) were fulfilled by 51 patients (29 men, 22 women; mean age 61 +/- 14 years). Structural heart disease was present in 31 patients; the atrial fibrillation was idiopathic in 18 (35%). All 51 patients could be classified within the three classes and their subgroups: 14 patients (27%) in Class I, 13 (25%) in Class II, and 24 (47%) in Class III. The incidences of idiopathic atrial fibrillation were 21%, 30%, and 45% of the patients in Classes I, II, and III, respectively.
CONCLUSIONS: Based on this new classification system, all hospitalized patients with paroxysmal atrial fibrillation could be classified. This classification may be useful to delineate better the clinical subgroups of patients with paroxysmal atrial fibrillation, to characterize better the patient population in future studies, and to improve treatment strategies.

Entities:  

Mesh:

Year:  1995        PMID: 7743011     DOI: 10.1111/j.1540-8167.1995.tb00758.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  6 in total

Review 1.  Challenges in the classification of atrial fibrillation.

Authors:  Steven A Lubitz; Emelia J Benjamin; Jeremy N Ruskin; Valentin Fuster; Patrick T Ellinor
Journal:  Nat Rev Cardiol       Date:  2010-06-22       Impact factor: 32.419

Review 2.  A review of atrial fibrillation.

Authors:  David Dang; Raluca Arimie; L Julian Haywood
Journal:  J Natl Med Assoc       Date:  2002-12       Impact factor: 1.798

3.  Associations between Cardioembolic Stroke and Obstructive Sleep Apnea.

Authors:  Melissa C Lipford; Kelly D Flemming; Andrew D Calvin; Jay Mandrekar; Robert D Brown; Virend K Somers; Sean M Caples
Journal:  Sleep       Date:  2015-11-01       Impact factor: 5.849

4.  Paroxysmal atrial fibrillation in cryptogenic stroke.

Authors:  Neha S Dangayach; Kevin Kane; Majaz Moonis
Journal:  Ther Clin Risk Manag       Date:  2011-01-28       Impact factor: 2.423

5.  Association of Atrial Fibrillation Episode Duration With Arrhythmia Recurrence Following Ablation: A Secondary Analysis of a Randomized Clinical Trial.

Authors:  Jason G Andrade; Marc W Deyell; Atul Verma; Laurent Macle; Jean Champagne; Peter Leong-Sit; Paul Novak; Mariano Badra-Verdu; John Sapp; Paul Khairy; Stanley Nattel
Journal:  JAMA Netw Open       Date:  2020-07-01

Review 6.  Paroxysmal Atrial Fibrillation in Horses: Pathophysiology, Diagnostics and Clinical Aspects.

Authors:  Sofie Troest Kjeldsen; Sarah Dalgas Nissen; Rikke Buhl; Charlotte Hopster-Iversen
Journal:  Animals (Basel)       Date:  2022-03-10       Impact factor: 2.752

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.